Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$26.91 USD
-0.26 (-0.96%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $26.91 0.00 (0.00%) 7:32 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 141 - 160 ( 195 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q4/FY19; Ensifentrine/COPD: End-of-Ph2 Meeting in Q2; Potential Ph3 Start in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/COPD: Ph2b Data Published; Next-Topline Ph2 pMDI Results in Q1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Positive Topline Results for Phase 2b Ensifentrine Add-on Therapy for COPD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q3 Financials Uneventful; Top-line Ensifentrine/COPD Phase 2b Data Around YE
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/COPD: Ph2b Fully Enrolled; Data Release by YE; Ph3 Starts in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/DPI: Positive Interim Ph2 Data at ERS Supports Future Partnership
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q2; Cash Runway into Q2:20; Attractive Valuation in Front of Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Positive DPI Phase 2 Results Expands Ensifentrine COPD Commercial Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine/COPD: Key Catalysts in H2; Ph3 to Start in 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine MDI Phase 2 Trial Initiated; Interim Data in H2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.